RFA-NS-23-007: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to small businesses. Applications closed on April 4, 2025.
From the official notice on Grants.gov, last changed September 15, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsNot allowed
- Funded byNIGMS, NIDCR, NICHD
- Median yearly award$349,855
- Typical project length2 years
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under RFA-NS-23-007 were run by National Institute of General Medical Sciences (NIGMS, 3 projects), National Institute of Dental and Craniofacial Research (NIDCR, 1 project), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 1 project) and National Heart Lung and Blood Institute (NHLBI, 1 project), and 1 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-23-007 in the NIH Guide.
Key dates
| Posted | September 15, 2022 |
|---|---|
| Deadline | April 4, 2025 |
| Archived by Grants.gov | May 10, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowe
Is this a realistic fit?
- Most of the money in the 16 programs behind this notice (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
Funded under RFA-NS-23-007 so far
NIH funded 7 projects under RFA-NS-23-007 in fiscal 2023 to 2026, at 7 institutions. The median yearly award was $349,855.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Nanodroplet Infused Analgesic-Wafer for Transmucosal Opioid-free Treatment of Subacute Oral Pain | Trekka Therapeutics, LLC | 2026 | $283,223 |
| Development of Allosteric Uncouplers as Therapeutics for Chronic Pain | Unco Therapeutics LLC | 2025 | $350,000 |
| An Innovative AI-Powered Wearable Physiological Sensor System for Real-Time Pain Monitoring and Management (PainVitals) | Aventusoft, LLC | 2025 | $349,855 |
| Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain | Epigen Biosciences, Inc. | 2025 | $349,999 |
| Validating SER-014, a TRPV1 antagonist, to treat endometriosis | Serentrix, LLC | 2024 | $384,418 |
| Chest Tube with Sustained Release of Local Anesthetic Agents for Pain Reduction in Cardiothoracic Surgeries | Medical Elution Devices LLC | 2024 | $275,752 |
| Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief | Vanish Therapeutics Inc. | 2024 | $346,517 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Other programs behind this notice
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Mental Health Research Grants
- Child Health and Human Development Extramural Research
- Cancer Treatment Research
- Cancer Biology Research
- Cancer Cause and Prevention Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Research Infrastructure Programs
- Research and Training in Complementary and Integrative Health
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-23-007 still open?
No. It closed on April 4, 2025.
Who can apply for HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)?
Closed April 4, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-NS-23-007?
NIH RePORTER lists 7 projects funded under RFA-NS-23-007 in fiscal 2023 to 2026, at 7 institutions. The most were at Trekka Therapeutics, LLC, Unco Therapeutics LLC, Aventusoft, LLC.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)